H.C. Wainwright lowered the firm’s price target on EyePoint to $30 from $33 and keeps a Buy rating on the shares following the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- Biotech Alert: Searches spiking for these stocks today
- EyePoint reports Q1 EPS (55c), consensus (42c)
- EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
- EyePoint price target lowered to $38 from $46 at Baird
- EyePoint price target lowered to $28 from $39 at Chardan